| Trial | Studied treatment | Control treatment | patients | ROB | Result | NCT |
|---|
|
|
| MERLIN TIMI 36, 2007 | ranolazine | placebo | | | Suggesting | NCT00099788 |
|
|
| APPRAISE-1 (10mg od), 2009 | apixaban | placebo | | Exploratory | Negative | NCT00313300 |
| APPRAISE-1 (2.5 mg bid), 2009 | apixaban | placebo | | | Negative | NCT00313300 |
| APPRAISE 2, 2011 | apixaban | placebo | | Low risk of bias | Negative | NCT00831441 |
| APPRAISE japan ongoing | apixaban | placebo | | Exploratory | - | NCT00852397 |
|
| ARGAMI-2, 1998 | Argatroban | heparin | | | - | |
|
| VA-pilot | aspirin | placebo | | | Negative | |
| ALDUSA-pilot | aspirin | placebo | | | Negative | |
| VA-main, 1983 | aspirin | placebo | | | Suggesting | |
| Canadian (Aspirin + sulfinpyrazone), 1985 | aspirin + sulfinpyrazone | placebo | | | Negative | |
| Canadian (Aspirin vs PBO), 1985 | aspirin | placebo | | | - | |
| Théroux, 1988 | aspirin | placebo | | | Suggesting | |
| ATACS-pilot, 1990 | aspirin | control | | | Negative | |
| RISC, 1990 | aspirin | placebo | | | Suggesting | |
|
| LANCELOT ACS | atopaxar | placebo | | Exploratory | - | |
| J-LANCELOT, 2010 | atopaxar | placebo | | Exploratory | - | |
|
| BAT (Bittl), 1995 | bivalirudin | heparin | | Low risk of bias | Suggesting | |
| HERO, 1997 | bivalirudin | heparin | | Exploratory | Suggesting | |
| PROTECT-TIMI 30, 2006 | bivalirudin | eptifibatide + heparin | | Exploratory | - | NCT00250471 |
| ACUITY (biva alone vs hep+aGP2b3a), 2006 | bivalirudin | heparin + GP2b3a inhibitors | | | Suggesting | NCT00093158 |
| ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | Negative | NCT00093158 |
| ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | Negative | |
| ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 | bivalirudin | heparin + GP2b3a inhibitors | | | Suggesting | |
|
| CURE, 2001 | clopidogrel + aspirin | aspirin | | | Suggesting | |
| CURE (PCI sub study), 2001 | clopidogrel | placebo | | Exploratory | - | |
| CURRENT OASIS 7 (clopidogrel), 2010 | clopidogrel high-dose regimen | clopidogrel standard-dose | | Low risk of bias | Negative | NCT00335452 |
|
| ASPECT-2 (coumadin vs aspirin), 2002 | coumadin | aspirin | | | Suggesting | |
| ASPECT-2 (coumadin+asp vs asp), 2002 | coumadin | control (on top of aspirin) | | | Suggesting | |
|
| REDEEM, 2009 | dabigatran | placebo | | | Negative | NCT00621855 |
|
| FRISC (long term), 1996 | dalteparin | placebo (on top of aspirin) | | Exploratory | Suggesting | |
| FRISC (short term), 1996 | dalteparin | placebo (on top of aspirin) | | Low risk of bias | - | |
| FRIC prolonged treatment phase (LWMH vs PBO), 1997 | dalteparin | placebo (on top of aspirin) | | | Negative | |
| FRIC (acute phase LMWH vs UFH), 1997 | dalteparin | UFH (on top of aspirin) | | Exploratory | Negative | |
|
| Prandoni, 1991 | aspirin + dipyridamol | placebo | | | Negative | |
|
| Klootwijk, 1999 | Efegatran | heparin | | Exploratory | - | |
|
| RESCUE | enoxaparin | unfractionated heparin | | | - | NCT00077818 |
| ESSENCE, 1997 | enoxaparin | UFH (on top of aspirin) | | | Suggesting | |
| TIMI 11 B (short term), 1998 | enoxaparin | UFH (on top of aspirin) | | | Suggesting | |
| TIMI 11 B (long term), 1998 | enoxaparin | UFH (on top of aspirin) | | | Negative | |
| EVET, 2005 | enoxaparin | tinzaparin | | | Suggesting | |
| SYNERGY, 2005 | enoxaparin | UFH (on top of aspirin) | | | Negative | NCT00043784 |
| INTERACT, 2006 | enoxaparin | UFH (on top of aspirin) | | | Suggesting | |
|
| PENTUA, 2004 | fondaparinux | enoxaparin | | | - | |
| OASIS 5, 2006 | fondaparinux | enoxaparin | | | - | NCT00139815 |
|
| HELVETICA (Serruys), 1995 | Hirudin | heparin | | Low risk of bias | - | |
| TIMI 9B, 1996 | Hirudin | heparin | | Risk of bias | - | |
| GUSTO IIB, 1996 | Hirudin | heparin | | Risk of bias | - | |
| OASIS pilot, 1997 | Hirudin | heparin | | Exploratory | - | |
| OASIS, 1997 | Hirudin | heparin | | Risk of bias | - | |
| HIT-4, 1999 | Hirudin | heparin | | Exploratory | - | |
| OASIS 2, 1999 | Hirudin | heparin | | Low risk of bias | - | |
|
| TRIM, 1997 | Inogatran | heparin | | Exploratory | - | |
|
| FRAXIS (6days), 1998 | nadroparin | UFH (on top of aspirin) | | Low risk of bias | Negative | |
| FRAXIS (14 days), 1998 | nadroparin | UFH (on top of aspirin) | | | Negative | |
|
| SEPIA-ACS1 TIMI 42, 2009 | otamixaban | unfractionated heparin | | Exploratory | Suggesting | NCT00317395 |
|
| TRITON-TIMI 38, 2007 | prasugrel | clopidogrel | | Low risk of bias | Suggesting | NCT00097591 |
| TRILOGY ACS (overall population), 2012 | prasugrel | clopidogrel | | Low risk of bias | Negative | NCT00699998 |
| ACAPULCO ongoing | prasugrel | clopidogrel | | | - | |
|
| ATLAS ACS-TIMI 46 (5mg), 2009 | rivaroxaban 5mg | placebo | | | Negative | NCT00402597 |
| ATLAS ACS-TIMI 46 (2.5mg), 2009 | rivaroxaban 2.5mg | placebo | | | Negative | NCT00402597 |
| ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 | rivaroxaban 2.5mg | placebo | | Low risk of bias | Suggesting | NCT00809965 |
| ATLAS ACS 2 - TIMI 51 (5mg), 2011 | rivaroxaban 5mg | placebo | | | Suggesting | NCT00809965 |
|
| Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone | placebo | | | - | |
|
| DISPERSE-2 (90mg), 2007 | ticagrelor | clopidogrel | | Exploratory | Negative | |
| PLATO, 2009 | ticagrelor | clopidogrel | | Low risk of bias | Suggesting | NCT00391872 |
|
| Florida UA | ticlopidine | placebo | | | Negative | |
| STAI, 1990 | ticlopidine | control | | | Suggesting | |
|
| Modena | trapidil | placebo | | | Suggesting | |
|
| Plaza, 1993 | triflusal | placebo | | | Suggesting | |
|
| Theroux (heparin+ASP vs ASP), 1988 | UFH | control (on top of aspirin) | | | Suggesting | |
| Theroux (heparin+aspirin vs PBO), 1988 | UFH + aspirin | placebo | | | Suggesting | |
| Theroux (heparin vs PBO), 1988 | UFH | placebo | | | Suggesting | |
| Cohen (ATACS pilot) (heparin vs asp), 1990 | UFH, warfarin | aspirin | | | Negative | |
| Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 | UFH, warfarin | control (on top of aspirin) | | | Negative | |
| RISC (heparin+aspirin vs ASP), 1990 | UFH | control (on top of aspirin) | | | Negative | |
| RISC (heparin vs PBO), 1990 | UFH | placebo | | | Negative | |
| RISC (ASP+ heparin vs PBO), 1990 | UFH + aspirin | placebo | | | Suggesting | |
| ATACS (Cohen), 1994 | UFH, warfarin | control (on top of aspirin) | | | Negative | |
| Holdright, 1994 | UFH | control (on top of aspirin) | | | Negative | |
| Gurfinkel (UFH+aspririn vs aspirin), 1995 | UFH | placebo (on top of aspirin) | | | Negative | |
|
| ATACS (pilot study) warfarin vs aspirin, 1990 | warfarin | aspirin | | | Negative | |
| ATACS (pilot study) (warfarin vs control), 1990 | warfarin | control (on top of aspirin) | | | Negative | |
| ATACS, 1994 | warfarin | control (on top of aspirin) | | | Negative | |
| CARS, 1997 | warfarin | control (on top of aspirin) | | | Negative | |
| Williams, 1997 | warfarin | placebo (on top of aspirin) | | | Negative | |
| OASIS Pilot (phase 1), 1998 | warfarin | control (on top of aspirin) | | | Negative | |
| OASIS Pilot (phase 2), 1998 | warfarin | control (on top of aspirin) | | | Negative | |
| OASIS-2 Warfarin Substudy, 2001 | warfarin | control (on top of aspirin) | | | Negative | |
| Huyhn, 2001 | warfarin | placebo (on top of aspirin) | | | Negative | |
| APRICOT-2, 2002 | warfarin | control (on top of aspirin) | | | Negative | |
| CHAMP, 2002 | warfarin | control (on top of aspirin) | | | Negative | |
| WARIS, 2002 | warfarin | control (on top of aspirin) | | | Suggesting | |
| LoWASA, 2004 | warfarin | control (on top of aspirin) | | | Negative | |
| Zibaeenezhad, 2004 | warfarin | control (on top of aspirin) | | | Negative | |
|
| ESTEEM, 2003 | ximelagatran | placebo | | Exploratory | - | |
|
|
| DRS, 1986 | diltiazem | placebo | | | - | |
| Göbel (Dutch study), 1995 | diltiazem | placebo | | | - | |
|
| HINT (nifedipine vs metoprolol), 1988 | nifedipine | metoprolol | | | - | |
|
|
| MIRACL, 2001 | atorvastatin | placebo | acute coronary syndrome | Low risk of bias | Suggesting | |
| Colivicchi, 2002 | atorvastatin | usual care | acute coronary syndrome | Exploratory | Negative | |
| PROVE IT - TIMI 22, 2004 | atorvastatin | pravastatin | acute coronary syndrome | | Suggesting | |
| ESTABLISH, 2004 | atorvastatin | usual care | acute coronary syndrome | Exploratory | Negative | |
|
| LIPS (sub groups), 2002 | fluvastatin | placebo | acute coronary syndrome | Exploratory | Negative | |
| FLORIDA, 2002 | fluvastatin | placebo | acute coronary syndrome | Low risk of bias | Negative | |
| Czech trial ongoing | fluvastatin | placebo | acute coronary syndrome | Exploratory | - | NCT00171275 |
|
| LAMIL, 1997 | pravastatin | placebo | acute coronary syndrome | Exploratory | Negative | |
| RECIFE, 1999 | pravastatin | placebo | acute coronary syndrome | Exploratory | Negative | |
| L-CAD, 2000 | pravastatin | usual care | acute coronary syndrome | Exploratory | Suggesting | |
| PAIS, 2001 | pravastatin | placebo | acute coronary syndrome | Exploratory | Negative | |
| PTT, 2002 | pravastatin | usual care | acute coronary syndrome | Exploratory | Suggesting | |
| PACT, 2004 | pravastatin | placebo | acute coronary syndrome | Low risk of bias | Suggesting | |
|
| A to Z, 2004 | simvastatin | placebo | acute coronary syndrome | | Negative | |
|
|
| UNASEM, 1992 | anistreplase | placebo | | Exploratory | - | |
|
| Gold, 1987 | t-PA | placebo | | Exploratory | - | |
| Topol, 1988 | t-PA | placebo | | Exploratory | Negative | |
| Nicklas, 1989 | t-PA | placebo | | Exploratory | Negative | |
| Williams, 1990 | t-PA | placebo | | Exploratory | Negative | |
| Ardissino, 1990 | t-PA | placebo | | Exploratory | Negative | |
| van der Brand, 1991 | t-PA | placebo | | Exploratory | Negative | |
| Freeman, 1992 | t-PA | placebo | | Low risk of bias | Negative | |
| charbonnier, 1992 | t-PA | placebo | | Exploratory | - | |
| TIMI 3A, 1993 | t-PA | placebo | | Exploratory | - | |
| TIMI 3B, 1995 | t-PA | placebo | | Low risk of bias | - | |
|
|
| Karlberg, 1998 | | placebo | | | - | |
| Doucet, 2000 | | placebo | | | - | |